Tafalgie Therapeutics, a biopharmaceutical research company specializing in the development of treatments for relieving and preventing acute and chronic pain (inflammatory, postoperative, neuropathic) without adverse effects, is pleased to announce that its teams are today moving to a new site with dedicated research and support functions in Luminy, Marseille, France.

Tafalgie has chosen to establish its headquarters at the Marseille-Luminy Technology Park (CCIMP Building), placing the company close to both its main partner laboratories (IBDM, AFMB) and Marseille University Hospital (AP-HM). The new facilities will bring all the teams together at a single site covering an area of almost 300 m², with a well-designed collaborative workspace to support its growth and to welcome its new employees in the best possible conditions.

Tafalgie Therapeutics will be able to accelerate all its development projects while improving the working environment and conditions for its employees.

“We are both delighted and proud to be moving into these new premises, which will enable us to bring together the various teams that were previously scattered over several sites, and to prepare for the projected strong growth in the number of staff.

These facilities will provide optimal working conditions. This is a further step towards our ambition to make Tafalgie Therapeutics a European platform of excellence in the field of pain treatments with the ability to attract large numbers of world-class scientists and to provide healthcare practitioners and patients with new, effective non-opioid therapeutic solutions without side effects”.



Eric Schettini, CEO of Tafalgie Therapeutics